Aurora Kinase Inhibitors
Aurora kinases are a family of highly conserved serine/threonine kinases that play indispensable roles in the orchestration of mitosis, ensuring the accurate segregation of chromosomes and the successful completion of cytokinesis. In humans, the family consists of three members: Aurora A, Aurora B, and Aurora C. Aurora A is primarily localized to the centrosomes and spindle poles during prophase and metaphase, where it regulates centrosome maturation and spindle assembly. Aurora B is a key component of the chromosomal passenger complex (CPC) and is responsible for chromosome-microtubule attachment, the spindle assembly checkpoint, and cytokinesis. Aurora C is mainly expressed in germ cells and is involved in meiosis. Because Aurora A and B are frequently overexpressed in a wide variety of solid and hematological malignancies, and their overexpression is often associated with aneuploidy and poor prognosis, they have become major targets for anti-cancer drug development.
Aurora Kinase inhibitors (AKIs) are generally classified into two categories: pan-Aurora inhibitors that target both Aurora A and B (such as tosedostat or danusertib) and selective inhibitors that target a specific isoform. Alisertib (MLN8237) is the most well-known selective Aurora A inhibitor and has reached advanced clinical trials for various cancers, including T-cell lymphoma and small cell lung cancer. Inhibition of Aurora A typically leads to spindle defects and mitotic delay, while inhibition of Aurora B results in the failure of cytokinesis and the formation of polyploid cells, which eventually undergo apoptosis or senescence. This phenotypic difference is a key consideration in clinical trial design. Despite the strong biological rationale, the clinical success of AKIs as monotherapies has been modest. Common dose-limiting toxicities include neutropenia, bone marrow suppression, and gastrointestinal issues, which are largely due to the essential role of Aurora kinases in the proliferation of normal hematopoietic cells.
Current research is focused on identifying the optimal scheduling of these drugs and exploring combination therapies to enhance their efficacy. For instance, combining AKIs with taxanes or other microtubule-targeting agents has shown synergistic effects in preclinical models, although managing overlapping toxicities remains a challenge. Another promising area is the combination of Aurora A inhibitors with inhibitors of the MYC oncogene, as Aurora A has been shown to stabilize N-MYC in certain cancers like neuroblastoma. Resistance to AKIs can emerge through mutations in the kinase domain or the upregulation of efflux pumps like ABCB1. Future directions in the field include the development of next-generation inhibitors with improved selectivity profiles and the search for predictive biomarkers, such as Aurora Kinase gene amplification or specific mitotic signatures, to better identify patient populations that will derive the most benefit. The ongoing exploration of Aurora inhibitors in the context of synthetic lethality and their potential to enhance the immunogenicity of tumors through the induction of chromosomal instability also represents an exciting frontier in precision oncology.
